Book a meeting
DO-BO

What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement.

The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as the Inflation Reduction Act. As fragmentation and rising complexity are pushing pharma to rethink strategy and timelines – this is a must-listen for professionals in pricing, HEOR, and market access.

Related

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By

Stefan Walzer

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)

By

Stefan Walzer

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

Is the EU “Launch Obligation” Really as Scary as It Sounds, Dr. Alexander Natz?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]